Forian Stock Soars 29% Amid Insider Stake Disclosures and RWE Showcase
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Forian Inc. (NASDAQ: FORA) is a publicly traded healthtech company that provides software-as-a-service solutions, proprietary data, and predictive analytics to healthcare providers, payers, and life sciences firms. Its primary platform, the Forian Data Factory, ingests and normalizes fragmented healthcare information in compliance with HIPAA regulations. On August 25, 2025, FORA shares closed at USD 2.29, reflecting a 29.38 percent increase on a trading volume of 326,151 shares.
| Ticker | Exchange | Price (USD) | Change (%) | Volume |
|---|---|---|---|---|
| FORA | NASDAQ | 2.29 | +29.38 | 326,151 |
Corporate Structure
Headquartered in Newtown, Pennsylvania, Forian employs between 51 and 200 staff members, focusing on technology, data science, and operations. The leadership team includes professionals with experience from companies such as WebMD and IQVIA. Adam Dublin serves as co-founder and Chief Strategy Officer, overseeing corporate strategy, data acquisition, and partnership development. Michael Vesey is the Chief Financial Officer, supported by directors in information technology, security, and product management.
Healthtech by Greg Rosenke
Developments and News
On January 27, 2025, Forian filed a Schedule 13D with the U.S. Securities and Exchange Commission, reporting that Max C. Wygod and Emily Bushnell each hold more than 12 percent of the company’s outstanding shares. As of November 12, 2024, there were a total of 31,016,379 shares outstanding. In August 2025, Forian announced its participation as an exhibitor and sponsor at the DIA Real-World Evidence Conference scheduled for October 2025, where it plans to present its hybrid claims ecosystem, CHRONOS™, and the referral-network analytics tool, Chartis by Forian.
Financial and Strategic Aspects
Forian’s market capitalization is affected by concentrated ownership, with Wygod holding 13.7 percent of voting power and Bushnell holding 12.7 percent. The company has not publicly reported revenue figures. Its strategic focus includes real-world evidence (RWE), patient registries, and commercial analytics. The Data Factory integrates billions of de-identified patient records and employs artificial intelligence and proprietary taxonomies to support operational, clinical, and financial enhancements for its clients.
Market Position and Industry Context
In the healthcare analytics sector, Forian competes with established RWE and data-management platforms. The company distinguishes itself through an integrated SOC-2 and HIPAA-compliant environment, leveraging leadership experience from WebMD and IQVIA. The demand for platforms that provide insights into treatment patterns and patient journeys is increasing, particularly as life sciences companies and payers seek comprehensive data solutions. Forian’s hybrid model connects closed and open claims data through its CHRONOS™ offering, aligning with this evolving market trend.
tl;dr
On August 25, 2025, FORA shares increased by 29.38 percent to USD 2.29 on substantial trading volume. A Schedule 13D filing on January 27, 2025, disclosed that two investors control over 26 percent of outstanding stock. Forian plans to showcase its CHRONOS™ claims ecosystem and Chartis analytics tool at the DIA Real-World Evidence Conference in October 2025. Ongoing governance shifts and platform introductions may influence investor interest through the end of the year.